Mesoblast hits 50% enrolment for back pain trial Australian Life Scientist Mesoblast (ASX:MSB) has enrolled 50% of patients in its phase II trial of adult stem cells to treat chronic back pain . The Melbourne-based regenerative medicine company is investigating the use of off-the-shelf mesenchymal precursor cells (MPCs) for ... and more?? Read more »
Therapies to Treat Chronic Back Pain and Arthritis Pain Will Continue to Be … – Business Wire (press release)
Therapies to Treat Chronic Back Pain and Arthritis Pain Will Continue to Be ... Read more »
A pain in the back – Mirror.co.uk
A pain in the back Mirror.co.uk Back pain is an enduring problem with up to four out of five people suffering at some point in their lives. This puts a huge drain on the economy and the NHS. Our ideas about the best ways to treat chronic ... Read more »
Benefits of duloxetine in chronic low-back pain unclear – Clinical Advisor
Benefits of duloxetine in chronic low- back pain unclear Clinical Advisor The FDA has approved duloxetine (Cymbalta) to treat chronic musculoskeletal pain, including discomfort from osteoarthritis and chronic low- back pain . ... Read more »
Sydney scientists beat pain with spinal chip – Modern Ghana
The device could be used to treat chronic back pain, leg pain and pain from nerve damage, but could also help those suffering from migraines, Parkinson's disease tremors or epileptic seizures. NICTA wants to commercialise the technology in Sydney, planning ... Read more »
Sydney scientists beat pain with spinal chip – ZDNet Australia
The device could be used to treat chronic back pain, leg pain and pain from nerve damage, but could also help those suffering from migraines, Parkinson's disease tremors or epileptic seizures. NICTA wants to commercialise the technology in Sydney, planning ... Read more »
Replication Medical Receives Grant of Nearly $250,000.00 on the Heels of Successful Clinical … – Melodika.net
The GelStix product is intended to treat chronic lower back pain which impacts nearly 10-15% of adults and is associated with a condition known as degenerative disc disease. GelStix received the CE Mark in early 2010 and is now available for sale and ... Read more »
FDA clears drug used to treat depression for chronic musculoskeletal pain – Ortho SuperSite
The FDA recently approved duloxetine hydrochloride to treat chronic musculoskeletal pain, including discomfort from osteoarthritis and chronic lower back pain, according to an FDA press release. Read more »
FDA approves Cymbalta for treatment of chronic musculoskeletal pain – News-Medical.Net
The U.S. Food and Drug Administration today approved Cymbalta (duloxetine hydrochloride) to treat chronic musculoskeletal pain, including discomfort from osteoarthritis and chronic lower back pain Read more »
FDA Approves Cymbalta for Chronic Musculoskeletal Pain – MedicineNet.com
Nov. 5, 2010 -- A drug used to treat depression , anxiety , fibromyalgia , and diabetic neuropathy has been approved by the FDA for a new use -- to treat chronic musculoskeletal pain, including pain caused by osteoarthritis and chronic low back pain. Read more »
